Hansa Biopharma Announces First Commercial Kidney Transplant Patient Treated with Idefirix in Australia
Outcomes will be tracked in an Australian registry as the treatment is used commercially for highly sensitized kidney transplant candidates.
7 Articles
7 Articles
PR Newswire
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living...
New Treatment Expands Kidney Transplant Options in Australia
What Happened? Hansa Biopharma, a Swedish company, announced that the first patient in Australia has successfully received a kidney transplant after being treated with a new medication called Idefirix® (imlifidase). This is an important milestone because this treatment helps patients who face major obstacles to getting a transplant. Why This Matters for Patients The Problem […]
Specialist pharmaceutical company Hansa Biopharma announces that the first commercial patient in Australia has been treated with Idefirix (imlifidaze) for a living donor kidney transplant, in accordance with the indication approved by the Australian Medicines Agency. This is according to a press release.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
